August 19, 2016 06:34 AM EDT

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

John Carroll

Editor & Founder

The new gene editing joint venture being formed by Bayer and CRISPR Therapeutics is taking shape. Now dubbed Casebia Therapeutics, the fledgling operations has begun …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

Wel­come Case­bia, the $335M gene edit­ing JV hatched by Bay­er and CRISPR Ther­a­peu­tics

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial